Gilead (GILD) says they have reached guidance number for Yeztugo in 2025 of USD 150mln after the launch in the middle of 2025, via JPM Conference

Gilead's guidance for Yeztugo at $150 million by 2025 marks a commitment to their biotech growth, indicating optimism post-launch.

Newsquawk StaffPublished On the live feed at 5 more headlines followed before this page went public
Newsquawk headlinesUTC

A bipartisan group of lawmakers, led by Senator Coons, is going to Greenland to meet with high-ranking Danish officials and business leaders

FCC says it has changed device unlocking rules that cost Verizon (VZ) "hundreds of millions of dollars each year"

Gilead (GILD) says they have reached guidance number for Yeztugo in 2025 of USD 150mln after the launch in the middle of 2025, via JPM Conference

US Senator Warren told US President Trump that congress could pass the interest rate cap

The White House is weighing a last-ditch Iranian offer to engage in diplomacy over curbing its nuclear programme even as President Trump currently leans toward authorising fresh military strikes on Iran, WSJ reports citing officials

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
  • Filed Anito-cel with FDA, awaiting a confirmation of acceptance letter they expect this quarter, and targeting launch for h2 2026
Context

While the projection reflects confidence, it's crucial to assess their FDA filing acceptance and market dynamics leading up to the product launch, as these factors will significantly shape investor sentiment and stock performance.

Related headlines

The whole workspace, free to try.

Try it free